Literature DB >> 27649688

Increased glucose-stimulated FGF21 response to oral glucose in obese nondiabetic subjects after Roux-en-Y gastric bypass.

S G Vienberg1, S H Jacobsen2,3, D Worm2, L E Hvolris4, L Naver4, T Almdal2, D L Hansen2, B S Wulff1, T R Clausen1, S Madsbad2, J J Holst3,5, B Andersen1.   

Abstract

OBJECTIVE: The positive metabolic outcome of Roux-en-Y gastric bypass (RYGB) surgery may involve fibroblast growth factor 21 (FGF21), in both the fasting state and postprandially. We measured the fasting levels of FGF21 before and after bariatric surgery as well as the postprandial FGF21 responses after a glucose load and after a mixed meal.
DESIGN: Observational intervention trial. PATIENTS AND MEASUREMENTS: Eight obese, nondiabetic patients underwent RYGB. Plasma FGF21 was measured both before and after surgery on three different days during oral glucose loads (25 g or 50 g glucose) or a mixed meal. Blood samples were taken right before the meal and at 15-min intervals until 90 min and at 150 min and 210 min relative to the start of the meal.
RESULTS: Overall, fasting plasma FGF21 did not change significantly before and after surgery (262 ± 71 vs 411 ± 119 pg/ml), but for three subjects, fasting plasma FGF21 increased significantly after surgery. Furthermore, FGF21 levels increased significantly at t = 90 and t = 150 min in response to 50 g glucose, but not after a mixed meal.
CONCLUSIONS: In conclusion, the observed increase in postprandial plasma FGF21 in response to glucose and the lack of FGF21 response to a mixed meal may have important implications for the physiologic role of FGF21. The increase in postprandial FGF21 in response to glucose in the early postoperative period may contribute to the metabolic improvements observed after gastric bypass.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649688     DOI: 10.1111/cen.13241

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Roux-en-Y Gastric Bypass Surgery Has Unique Effects on Postprandial FGF21 but Not FGF19 Secretion.

Authors:  Lydia-Ann L S Harris; Gordon I Smith; Bettina Mittendorfer; J Christopher Eagon; Adewole L Okunade; Bruce W Patterson; Samuel Klein
Journal:  J Clin Endocrinol Metab       Date:  2017-10-01       Impact factor: 5.958

Review 2.  Effects of Bariatric Surgeries on Fetuin-A, Selenoprotein P, Angiopoietin-Like Protein 6, and Fibroblast Growth Factor 21 Concentration.

Authors:  Jakub Poloczek; Wojciech Kazura; Ewa Kwaśnicka; Janusz Gumprecht; Jerzy Jochem; Dominika Stygar
Journal:  J Diabetes Res       Date:  2021-08-06       Impact factor: 4.011

3.  Ileal Transposition Surgery Decreases Fat Mass and Improves Glucose Metabolism in Diabetic GK Rats: Possible Involvement of FGF21.

Authors:  Kemin Yan; Weijie Chen; Huijuan Zhu; Guole Lin; Hui Pan; Naishi Li; Linjie Wang; Hongbo Yang; Meijuan Liu; Fengying Gong
Journal:  Front Physiol       Date:  2018-03-09       Impact factor: 4.566

4.  Transient postprandial increase in intact circulating fibroblast growth factor-21 levels after Roux-en-Y gastric bypass: a randomized controlled clinical trial.

Authors:  Mette S Nielsen; Susanna Søberg; Julie B Schmidt; Anne Chenchar; Anders Sjödin; Matthew P Gillum
Journal:  PeerJ       Date:  2021-04-14       Impact factor: 2.984

5.  Does FGF21 Mediate the Potential Decrease in Sweet Food Intake and Preference Following Bariatric Surgery?

Authors:  Mette S Nielsen; Christian Ritz; Anne Chenchar; Wender L P Bredie; Matthew P Gillum; Anders Sjödin
Journal:  Nutrients       Date:  2021-10-28       Impact factor: 5.717

6.  Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans.

Authors:  Thomas P J Solomon; Steven Carter; Jacob M Haus; Kristian Karstoft; Stephanie von Holstein-Rathlou; Mette S Nielsen; Matthew P Gillum
Journal:  PeerJ       Date:  2022-01-19       Impact factor: 2.984

Review 7.  The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model.

Authors:  Redin A Spann; Christopher D Morrison; Laura J den Hartigh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-03       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.